Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This CDC finding is limited by the fact that the data set did not include people who are incarcerated or experiencing homelessness.
Prescriptions in the household have long been cited as a source of individuals’ misuse of opioids.
A recent analysis found that about half of people with COVID-19, the disease caused by the coronavirus, have liver enzyme abnormalities.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
Researchers attribute this dramatic shift to routine testing and access to direct-acting antiviral treatment for hep C.
A recent Japanese study found that this risk reduction was greater than that associated with the hep B vaccine.
Alabama state pandemic guidance advises denying ventilators for use by people with metastatic cancer, AIDS and end-stage liver disease.
Instead of non-alcoholic fatty liver disease, they suggest calling it metabolic-associated fatty liver disease.
Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.
Just under 1% of pregnant women in the state overall up to 2% in central and western New York have hep C antibodies.
Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.
A recent analysis found that health care providers missed opportunities to test 90% of such patients.
Researchers believe this finding may have implications for human health.
Non-alcoholic steatohepatitis, the more severe form of non-alcoholic fatty liver disease, is highly prevalent in the HIV population.
A recent study found that providing opioid use disorder treatment was associated with a high hep C cure rate and less drug use.
Though low, this figure is three times the rate of discontinuation seen in clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.